A Swedish health technology startup, Yazen Health, has secured €19.5M ($21.27 million) in an oversubscribed Series A funding round backed by Preply and Bob W, Helsana HealthInvest, Almaz Capital, Luminar Ventures and Aggregate Media.
The new investment will help the company expand its obesity care globally, starting with the Netherlands, Spain, and Norway, where they already have a strong presence.
Additionally, the funding will support new markets in the UK and Germany. Yazen Health’s latest investment will also help fuel the company’s growth and expansion in the next two to three years, enhance its offerings, and expand into other countries.
According to the announcement, the new capital will also be vital in supporting the company’s efforts to help patients on their path toward achieving healthier lives by upgrading Yazen’s app and holistic care services.
Revolutionizing Weight Loss Treatment
Co-founded in 2021 by Fredrik Meurling, Henrik Bretz, Magnus Nyhlen MD, and Martin Carlsson, the Sweden-based weight loss startup has been gaining popularity with the wave of GLP-1 weight loss drugs such as Ozempic, Mounjaro, and Wegovy.
The company’s weight loss treatment solutions combine GLP-1 weight loss, diabetes treatments, and lifestyle change advice for improved therapy outcomes.
Yazen Health leverages a complete care model comprising a team of healthcare professionals, including dedicated doctors, psychologists, physiotherapists, dietitians, and Yazen coaches, delivering a comprehensive solution for more than 20,000 customers in Sweden with a 70% retention rate.
